RU2011115712A - Комбинации с фиксированной дозой алискирена и амлодипина в форме двухслойных или однослойных таблеток - Google Patents
Комбинации с фиксированной дозой алискирена и амлодипина в форме двухслойных или однослойных таблеток Download PDFInfo
- Publication number
- RU2011115712A RU2011115712A RU2011115712/15A RU2011115712A RU2011115712A RU 2011115712 A RU2011115712 A RU 2011115712A RU 2011115712/15 A RU2011115712/15 A RU 2011115712/15A RU 2011115712 A RU2011115712 A RU 2011115712A RU 2011115712 A RU2011115712 A RU 2011115712A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- granulate
- amlodipine
- aliskiren
- pharmaceutical oral
- Prior art date
Links
- 229940075710 aliskiren and amlodipine Drugs 0.000 title 1
- 239000007942 layered tablet Substances 0.000 title 1
- 239000008187 granular material Substances 0.000 claims abstract 52
- 229960004601 aliskiren Drugs 0.000 claims abstract 28
- 229960000528 amlodipine Drugs 0.000 claims abstract 28
- 239000000654 additive Substances 0.000 claims abstract 26
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims abstract 24
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims abstract 24
- 230000000996 additive effect Effects 0.000 claims abstract 19
- 239000000203 mixture Substances 0.000 claims abstract 16
- 150000001875 compounds Chemical class 0.000 claims abstract 10
- 150000003839 salts Chemical class 0.000 claims abstract 10
- 238000005469 granulation Methods 0.000 claims abstract 7
- 230000003179 granulation Effects 0.000 claims abstract 7
- 238000004090 dissolution Methods 0.000 claims abstract 6
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims abstract 5
- 239000007788 liquid Substances 0.000 claims abstract 5
- 238000000338 in vitro Methods 0.000 claims abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims 16
- 239000007888 film coating Substances 0.000 claims 9
- 238000009501 film coating Methods 0.000 claims 9
- 239000003085 diluting agent Substances 0.000 claims 8
- 239000010410 layer Substances 0.000 claims 7
- 239000007884 disintegrant Substances 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 239000002356 single layer Substances 0.000 claims 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- 239000000463 material Substances 0.000 claims 4
- 238000002156 mixing Methods 0.000 claims 4
- 238000007873 sieving Methods 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 2
- 235000010443 alginic acid Nutrition 0.000 claims 2
- 229920000615 alginic acid Polymers 0.000 claims 2
- 229960000913 crospovidone Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 238000005056 compaction Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 238000003825 pressing Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 238000005550 wet granulation Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9894508P | 2008-09-22 | 2008-09-22 | |
| US61/098,945 | 2008-09-22 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014140552/15A Division RU2014140552A (ru) | 2008-09-22 | 2009-09-22 | Комбинации с фиксированной дозой алискирена и амлодипина в форме двухслойных или однослойных таблеток |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011115712A true RU2011115712A (ru) | 2012-10-27 |
Family
ID=42040192
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011115712/15A RU2011115712A (ru) | 2008-09-22 | 2009-09-22 | Комбинации с фиксированной дозой алискирена и амлодипина в форме двухслойных или однослойных таблеток |
| RU2014140552/15A RU2014140552A (ru) | 2008-09-22 | 2009-09-22 | Комбинации с фиксированной дозой алискирена и амлодипина в форме двухслойных или однослойных таблеток |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014140552/15A RU2014140552A (ru) | 2008-09-22 | 2009-09-22 | Комбинации с фиксированной дозой алискирена и амлодипина в форме двухслойных или однослойных таблеток |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8613949B2 (enExample) |
| EP (1) | EP2328564A2 (enExample) |
| JP (2) | JP2012503020A (enExample) |
| KR (1) | KR20110060942A (enExample) |
| CN (1) | CN102159195A (enExample) |
| AR (1) | AR073384A1 (enExample) |
| AU (1) | AU2009292908B2 (enExample) |
| BR (1) | BRPI0919350A2 (enExample) |
| CA (1) | CA2736257A1 (enExample) |
| CL (1) | CL2011000594A1 (enExample) |
| CO (1) | CO6351711A2 (enExample) |
| EC (1) | ECSP11010999A (enExample) |
| IL (1) | IL211571A0 (enExample) |
| JO (1) | JO3239B1 (enExample) |
| MA (1) | MA32719B1 (enExample) |
| MX (1) | MX2011002988A (enExample) |
| MY (1) | MY153610A (enExample) |
| PE (1) | PE20110293A1 (enExample) |
| RU (2) | RU2011115712A (enExample) |
| TW (1) | TW201016217A (enExample) |
| WO (1) | WO2010033954A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2382969A1 (en) * | 2010-04-30 | 2011-11-02 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multicoated Aliskiren formulations |
| CN102247344A (zh) * | 2011-05-30 | 2011-11-23 | 北京阜康仁生物制药科技有限公司 | 一种新型降血压组合物 |
| CN103070863A (zh) * | 2011-10-25 | 2013-05-01 | 河南省健康伟业生物医药研究股份有限公司 | 阿利吉仑和氨氯地平/左旋氨氯地平的口服固体制剂的制备新工艺 |
| US20180338922A1 (en) * | 2017-05-26 | 2018-11-29 | Esperion Therapeutics, Inc. | Fixed dose formulations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003032954A1 (en) | 2001-10-17 | 2003-04-24 | Dr. Reddy's Laboratories Ltd. | Stabilized pharmaceutical formulations containing amlodipine maleate |
| HU226642B1 (en) | 2001-12-17 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Amlodipine bezylate tablets having extended stability and process for producing the same |
| KR20100137026A (ko) * | 2002-05-17 | 2010-12-29 | 노파르티스 아게 | 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물 |
| DE10223282B3 (de) | 2002-05-24 | 2004-02-05 | Orga Kartensysteme Gmbh | Verfahren, Computerprogramm und Computersystem für einen prepaid Telekommunikationsdienst |
| FR2853904B1 (fr) | 2003-04-15 | 2007-11-16 | Air Liquide | Procede de production de liquides hydrocarbones mettant en oeuvre un procede fischer-tropsch |
| RU2426532C2 (ru) * | 2004-03-17 | 2011-08-20 | Новартис Аг | Применение органических соединений |
| MY144477A (en) * | 2004-03-17 | 2011-09-30 | Novartis Ag | Galenic formulations of organic compounds |
| PL1814527T5 (pl) * | 2004-11-05 | 2021-08-02 | Boehringer Ingelheim International Gmbh | Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę |
| WO2006059217A1 (en) | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| US20060116435A1 (en) * | 2004-12-01 | 2006-06-01 | Housel Tyler L | High strength polyurethane foam |
| GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| PE20120542A1 (es) * | 2006-06-27 | 2012-05-14 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
| US20080161320A1 (en) | 2006-09-11 | 2008-07-03 | Xiong Cai | Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety |
| US8119841B2 (en) * | 2006-11-07 | 2012-02-21 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
-
2009
- 2009-09-17 JO JOP/2009/0348A patent/JO3239B1/ar active
- 2009-09-18 AR ARP090103591A patent/AR073384A1/es unknown
- 2009-09-21 TW TW098131810A patent/TW201016217A/zh unknown
- 2009-09-22 JP JP2011528052A patent/JP2012503020A/ja not_active Withdrawn
- 2009-09-22 US US13/063,955 patent/US8613949B2/en not_active Expired - Fee Related
- 2009-09-22 KR KR1020117009088A patent/KR20110060942A/ko not_active Withdrawn
- 2009-09-22 PE PE2011000647A patent/PE20110293A1/es not_active Application Discontinuation
- 2009-09-22 WO PCT/US2009/057750 patent/WO2010033954A2/en not_active Ceased
- 2009-09-22 RU RU2011115712/15A patent/RU2011115712A/ru unknown
- 2009-09-22 CA CA2736257A patent/CA2736257A1/en not_active Abandoned
- 2009-09-22 EP EP09736332A patent/EP2328564A2/en not_active Withdrawn
- 2009-09-22 MX MX2011002988A patent/MX2011002988A/es active IP Right Grant
- 2009-09-22 CN CN2009801369580A patent/CN102159195A/zh active Pending
- 2009-09-22 RU RU2014140552/15A patent/RU2014140552A/ru not_active Application Discontinuation
- 2009-09-22 AU AU2009292908A patent/AU2009292908B2/en not_active Ceased
- 2009-09-22 BR BRPI0919350A patent/BRPI0919350A2/pt not_active IP Right Cessation
- 2009-09-22 MY MYPI2011000931A patent/MY153610A/en unknown
-
2011
- 2011-03-03 IL IL211571A patent/IL211571A0/en unknown
- 2011-03-21 CL CL2011000594A patent/CL2011000594A1/es unknown
- 2011-03-25 CO CO11036957A patent/CO6351711A2/es not_active Application Discontinuation
- 2011-04-15 MA MA33780A patent/MA32719B1/fr unknown
- 2011-04-21 EC EC2011010999A patent/ECSP11010999A/es unknown
-
2014
- 2014-12-12 JP JP2014252210A patent/JP2015091830A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015091830A (ja) | 2015-05-14 |
| RU2014140552A (ru) | 2015-06-20 |
| TW201016217A (en) | 2010-05-01 |
| IL211571A0 (en) | 2011-05-31 |
| WO2010033954A2 (en) | 2010-03-25 |
| US20110165240A1 (en) | 2011-07-07 |
| BRPI0919350A2 (pt) | 2015-12-29 |
| US8613949B2 (en) | 2013-12-24 |
| JO3239B1 (ar) | 2018-03-08 |
| JP2012503020A (ja) | 2012-02-02 |
| CO6351711A2 (es) | 2011-12-20 |
| CN102159195A (zh) | 2011-08-17 |
| AU2009292908A1 (en) | 2010-03-25 |
| CL2011000594A1 (es) | 2011-08-05 |
| WO2010033954A3 (en) | 2010-10-21 |
| MY153610A (en) | 2015-02-27 |
| MX2011002988A (es) | 2011-04-11 |
| AU2009292908B2 (en) | 2012-07-26 |
| CA2736257A1 (en) | 2010-03-25 |
| EP2328564A2 (en) | 2011-06-08 |
| MA32719B1 (fr) | 2011-10-02 |
| AR073384A1 (es) | 2010-11-03 |
| ECSP11010999A (es) | 2011-06-30 |
| KR20110060942A (ko) | 2011-06-08 |
| PE20110293A1 (es) | 2011-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006136090A (ru) | Галеновы составы органических соединений | |
| CA2611114A1 (en) | An entacapone-containing oral dosage form | |
| RU2019110089A (ru) | Усовершенствованная машина и способ упаковки в растягивающуюся пленку изделий, подаваемых блоками или по отдельности | |
| JP2011500797A5 (enExample) | ||
| JP2004519440A5 (enExample) | ||
| RU2010116526A (ru) | Фармацевтическая комбинация алискирена и валсартана | |
| CN101219120B (zh) | 替米沙坦分散片及其制备方法 | |
| HRP20120134T1 (hr) | Stabilni i lako topivljivi pripravci kandesartan-cileksetila, dobiveni vlažnim granuliranjem | |
| EA034711B1 (ru) | Лекарственная композиция, содержащая ингибитор всасывания холестерина и ингибитор биосинтеза холестерина | |
| RU2014140552A (ru) | Комбинации с фиксированной дозой алискирена и амлодипина в форме двухслойных или однослойных таблеток | |
| CN104840460A (zh) | 一种含有缬沙坦和氨氯地平的药物组合物 | |
| RU2017134562A (ru) | Сложный фармацевтический состав, включающий амлодипин, лозартан и хлорталидон | |
| CN104254321A (zh) | 稳定性提高的药物制剂 | |
| RU2009101971A (ru) | Галеновый состав алискирена и гидрохлортиазида | |
| RU2011116122A (ru) | Галеновая композиция, включающая алискирен и способ ее получения экструзионной грануляцией из расплава | |
| JP2012503020A5 (enExample) | ||
| RU2010116530A (ru) | Галеновые композиции алискирена | |
| JP2012503665A5 (enExample) | ||
| RU2011142081A (ru) | Галеновые фиксированные комбинации валсартана и алискирена | |
| CN102423482B (zh) | 复方氨氯地平赖诺普利片的制备方法 | |
| EP2890368A1 (en) | Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate | |
| NO317771B1 (no) | Eprosartanarginyl-ladning-noytraliseringskompleks og en fremgangsmate for dets fremstilling og anvendelse derav | |
| RU2010116528A (ru) | Галеновые композиции, содержащие алискирен и валсартан | |
| CN103505460A (zh) | 一种制备氯沙坦钾氢氯噻嗪组合物的方法 | |
| CN101234095B (zh) | 一种定时释放制剂及其制备方法 |